Systemic Immune-Inflammation Index and Clinical Predictors of Atypical PRES in Eclampsia: Higher Blood Pressure and Inflammatory Burden Drive Multi-Regional Involvement
Abstract
1. Introduction
2. Materials and Methods
2.1. Study Design and Ethical Approval
2.2. Patient Selection and Inclusion Criteria
2.3. Neuroimaging Acquisition and Assessment
2.4. Clinical and Laboratory Data Collection
2.5. Statistical Analysis
3. Results
3.1. Study Population and Baseline Characteristics
3.2. Comparison of Typical and Atypical PRES Patterns
3.3. Neuroimaging Findings and Regional Distribution
3.4. Predictors of Atypical PRES Pattern
3.5. Immunological Profile and Inflammatory Burden in Typical vs. Atypical PRES
4. Discussion
4.1. Hypertension Threshold and the Sympathetic Innervation Hypothesis
4.2. The “Overflow Theory” of Multi-Regional Involvement
4.3. Clinical Implications and Obstetric Management
5. Limitations
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Fischer, M.; Schmutzhard, E. Posterior reversible encephalopathy syndrome. J. Neurol. 2017, 264, 1608–1616. [Google Scholar] [CrossRef] [PubMed]
- Triplett, J.; Kutlubaev, M.; Kermode, A.; Hardy, T. Posterior reversible encephalopathy syndrome (PRES): Diagnosis and management. Pract. Neurol. 2022, 22, 183–189. [Google Scholar] [CrossRef] [PubMed]
- Hinduja, A. Posterior Reversible Encephalopathy Syndrome: Clinical Features and Outcome. Front. Neurol. 2020, 11, 71. [Google Scholar] [CrossRef] [PubMed]
- Ollivier, M.; Bertrand, A.; Clarençon, F.; Gerber, S.; Deltour, S.; Domont, F.; Trunet, S.; Dormont, D.; Leclercq, D. Neuroimaging features in posterior reversible encephalopathy syndrome: A pictorial review. J. Neurol. Sci. 2017, 373, 188–200. [Google Scholar] [CrossRef] [PubMed]
- Anderson, R.; Patel, V.; Sheikh-Bahaei, N.; Liu, C.; Rajamohan, A.; Shiroishi, M.; Kim, P.; Go, J.; Lerner, A.; Acharya, J. Posterior Reversible Encephalopathy Syndrome (PRES): Pathophysiology and Neuro-Imaging. Front. Neurol. 2020, 11, 463. [Google Scholar] [CrossRef] [PubMed]
- Wen, Y.; Yang, B.; Huang, Q.; Liu, Y. Posterior reversible encephalopathy syndrome in pregnancy: A retrospective series of 36 patients from mainland China. Ir. J. Med. Sci. 2017, 186, 699–705. [Google Scholar] [CrossRef] [PubMed]
- Álvarez-Pabón, Y.; Beltrán-Avendaño, M.; Di Lizio-Miele, K. Síndrome de encefalopatía posterior reversible, eclampsia y síndrome de hellp. Rev. Chil. De Obstet. Y Ginecol. 2017, 82, 280–292. [Google Scholar] [CrossRef][Green Version]
- Bartynski, W. Posterior Reversible Encephalopathy Syndrome, Part 2: Controversies Surrounding Pathophysiology of Vasogenic Edema. Am. J. Neuroradiol. 2008, 29, 1043–1049. [Google Scholar] [CrossRef] [PubMed]
- Saad, A.; Chaudhari, R.; Wintermark, M. Imaging of Atypical and Complicated Posterior Reversible Encephalopathy Syndrome. Front. Neurol. 2019, 10, 964. [Google Scholar] [CrossRef] [PubMed]
- Srichawla, B.; Garcia-Dominguez, M.; Silver, B. The Central Variant of Posterior Reversible Encephalopathy Syndrome: A Systematic Review and Meta-Analysis. Neurol. Int. 2025, 17, 113. [Google Scholar] [CrossRef]
- Gewirtz, A.; Gao, V.; Parauda, S.; Robbins, M. Posterior Reversible Encephalopathy Syndrome. Curr. Pain Headache Rep. 2021, 25, 19. [Google Scholar] [CrossRef] [PubMed]
- Brewer, J.; Owens, M.; Wallace, K.; Reeves, A.; Morris, R.; Khan, M.; LaMarca, B.; Martin, J. Posterior reversible encephalopathy syndrome in 46 of 47 patients with eclampsia. Am. J. Obstet. Gynecol. 2013, 208, 468.e1-6. [Google Scholar] [CrossRef] [PubMed]
- Chiang, W.; Chen, P.; Chen, Y.; Chen, M. Atypical posterior reversible encephalopathy syndrome in a noncompliant hemodialysis patient: Case report and literature review. Hemodial. Int. 2019, 23, E100–E103. [Google Scholar] [CrossRef] [PubMed]
- Cipolla, M. Cerebrovascular function in pregnancy and eclampsia. Hypertension 2007, 50, 14–24. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X.; Chen, Y.; Fan, Y.; Gao, D.; Zhang, Z. NLR (neutrophil to lymphocyte ratio), PLR (platelet to lymphocyte ratio), and SII (systemic immune-inflammation index) reflect disease activity and renal remission in patients with lupus nephritis. Front. Immunol. 2025, 16, 1646276. [Google Scholar] [CrossRef] [PubMed]
- Mert, G.; Kaya, Ö.; Shahveranova, A.; Bıçakçı, Y. Comparison of magnetic resonance imaging, clinical, and laboratory findings in atypical and typical posterior reversible encephalopathy syndrome. Cukurova Med. J. 2025, 50, 883–889. [Google Scholar] [CrossRef]
- Incognito, G.; Genovese, F.; Incognito, D.; Volpicelli, A.; Chieppa, P.; Saponaro, C.; Palumbo, M. Postpartum HELLP syndrome associated with posterior reversible encephalopathy syndrome: A case report and literature review. Ital. J. Gynaecol. Obstet. 2022, 11, 005019. [Google Scholar] [CrossRef]
- Vennapusa, J.; Godavarthy, P.; Garikipaty, S.; Kulkarni, M.; Chippa, S. A (PRES)sing Matter: Two Cases of Posterior Reversible Encephalopathy Syndrome (PRES) in Pregnancy and Postpartum. Cureus 2025, 17, e79255. [Google Scholar] [CrossRef] [PubMed]
- Del Poggio, A.; Narcisi, L.; Mapelli, R.; Lombardi, L.; Falini, A.; Anzalone, N. Clinico-radiological correlations in posterior reversible encephalopathy syndrome: Toward a better understanding of its heterogeneous manifestations. Neuroradiology 2025, 67, 1791–1800. [Google Scholar] [CrossRef] [PubMed]




| Characteristic | Overall (n = 266) | Typical PRES (n = 234) | Atypical PRES (n = 32) | OR (95% CI) | p-Value |
|---|---|---|---|---|---|
| Demographics | |||||
| Maternal age (years) | 29.0 (25.0–32.0) | 28.9 ± 5.6 | 27.5 ± 4.8 | 0.95 (0.88–1.03) | 0.196 |
| Gestational age (weeks) | 34.6 (32.3–36.9) | 34.5 ± 3.3 | 34.7 ± 4.2 | 1.01 (0.91–1.13) | 0.387 |
| Parity ≥ 1, n (%) | 185 (69.5%) | 164 (70.1%) | 21 (65.6%) | 0.305 | |
| Clinical Findings | |||||
| Peak systolic BP (mmHg) | 179.0 (165.2–195.0) | 172.4 ± 18.5 | 191.6 ± 20.4 | 1.24 (1.12–1.38) | <0.001 * |
| Peak diastolic BP (mmHg) | 112.0 (103.0–121.0) | 108.2 ± 12.4 | 118.5 ± 14.2 | 1.16 (1.09–1.24) | <0.001 * |
| HELLP syndrome, n (%) | 29 (10.9%) | 21 (8.9%) | 8 (25.0%) | 3.38 (1.36–8.40) | 0.048 * |
| MgSO4 administered, n (%) | 264 (99.2%) | 232 (99.1%) | 32 (100%) | 1.000 | |
| Laboratory Parameters | |||||
| Platelets (×103/µL) | 165 (122–209) | 165.0 (122.0–208.8) | 163.5 (120.8–217.0) | 0.915 | |
| AST (U/L) | 66 (44–98) | 65.0 (43.2–98.0) | 75.5 (46.2–94.2) | 0.734 | |
| ALT (U/L) | 58 (38–86) | 58.5 (36.0–88.0) | 59.0 (46.5–80.2) | 0.703 | |
| Neuroimaging Features | |||||
| Time to imaging (hours) | 9.1 (5.9–14.2) | 8.8 (5.6–13.8) | 11.2 (7.4–16.5) | 0.342 | |
| Deep gray involvement, n (%) | 72 (27.1%) | 54 (23.1%) | 18 (56.3%) | 4.28 (2.04–8.99) | <0.001 * |
| Regions involved, count | 3 (2–3) | 2.1 ± 0.6 | 4.4 ± 1.2 | 2.08 (1.52–2.85) | <0.001 * |
| Maternal & Neonatal Outcomes | |||||
| Emergent C-section, n (%) | 253 (95.1%) | 223 (95.3%) | 30 (93.8%) | 0.660 | |
| ICU length of stay (days) | 4.0 (1.0–15.0) | 4.0 (1.0–15.0) | 4.0 (2.0–15.0) | 1.02 (0.92–1.14) | 0.691 |
| Mechanical ventilation, n (%) | 60 (22.6%) | 52 (22.2%) | 8 (25.0%) | 0.821 | |
| APGAR score (5th min) | 8 (7–9) | 8.0 (1.0–10.0) | 8.0 (5.0–10.0) | 0.98 (0.85–1.12) | 0.948 |
| Predictor | Adjusted OR | 95% CI | p-Value |
|---|---|---|---|
| Model 1: Clinical Factors | |||
| Maternal age (per year) | 0.96 | 0.89–1.03 | 0.254 |
| Peak systolic BP (per 10 mmHg) | 1.24 | 1.12–1.38 | <0.001 * |
| HELLP syndrome (yes) | 1.84 | 0.72–4.68 | 0.201 |
| Model 2: Neuroimaging Features | |||
| Regions involved (per region) | 2.08 | 1.52–2.85 | <0.001 * |
| Deep gray involvement (yes) | 1.62 | 0.82–3.21 | 0.165 |
| Time to imaging (per hour) | 0.98 | 0.94–1.02 | 0.342 |
| Parameters | Typical PRES (n = 234) | Atypical PRES (n = 32) | OR (95% CI) | p-Value |
|---|---|---|---|---|
| NLR (Neutrophil/Lymphocyte Ratio) | 6.42 ± 2.15 | 9.85 ± 3.42 | 1.32 (1.15–1.52) | <0.001 |
| PLR (Platelet/Lymphocyte Ratio) | 142.6 ± 45.2 | 188.4 ± 62.8 | 1.01 (1.00–1.02) | 0.011 |
| SII (Systemic Immune-Inflammation Index) | 1240.5 ± 310.2 | 1965.8 ± 450.6 | 1.14 (1.08–1.21) | <0.001 |
| CRP (mg/L) | 14.8 ± 8.4 | 28.6 ± 12.5 | 1.12 (1.06–1.19) | <0.001 |
| LDH (U/L) | 345.2 ± 88.6 | 512.4 ± 124.8 | 1.01 (1.00–1.02) | 0.004 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.
Share and Cite
İncebıyık, M.; Göçmen, A. Systemic Immune-Inflammation Index and Clinical Predictors of Atypical PRES in Eclampsia: Higher Blood Pressure and Inflammatory Burden Drive Multi-Regional Involvement. Biomedicines 2026, 14, 862. https://doi.org/10.3390/biomedicines14040862
İncebıyık M, Göçmen A. Systemic Immune-Inflammation Index and Clinical Predictors of Atypical PRES in Eclampsia: Higher Blood Pressure and Inflammatory Burden Drive Multi-Regional Involvement. Biomedicines. 2026; 14(4):862. https://doi.org/10.3390/biomedicines14040862
Chicago/Turabian Styleİncebıyık, Mehmet, and Adalet Göçmen. 2026. "Systemic Immune-Inflammation Index and Clinical Predictors of Atypical PRES in Eclampsia: Higher Blood Pressure and Inflammatory Burden Drive Multi-Regional Involvement" Biomedicines 14, no. 4: 862. https://doi.org/10.3390/biomedicines14040862
APA Styleİncebıyık, M., & Göçmen, A. (2026). Systemic Immune-Inflammation Index and Clinical Predictors of Atypical PRES in Eclampsia: Higher Blood Pressure and Inflammatory Burden Drive Multi-Regional Involvement. Biomedicines, 14(4), 862. https://doi.org/10.3390/biomedicines14040862

